1-20 of 33
Hesham Mohamed
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Circulating Tumor DNA Analysis Associates with Progression-Free Survival (PFS) with Odronextamab Monotherapy in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and Diffuse Large B-Cell Lymphoma (DLBCL): Identification of Minimal Residual Disease Status and High-Risk Subgroups from the Phase 2 ELM-2 Study

Jon E. Arnason, Jurriaan Brouwer-Visser, Stefano Luminari, David Tucker, Tae Min Kim, Won Seog Kim, Laura Magnano, Dylan Sun, Jessica Cai, Kamil Cygan, Srikanth Ambati, Hesham Mohamed, Aafia Chaudhry, Vladimir Jankovic
Journal: Blood
Blood (2023) 142 (Supplement 1): 427.
https://doi.org/10.1182/blood-2023-179812
Published: 2023
Journal Articles

Odronextamab Monotherapy for the Treatment of Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and Diffuse Large B-Cell Lymphoma (DLBCL): Focus on Clinical Pharmacology and Pharmacometrics in the ELM-1 and ELM-2 Studies

Min Zhu, Daniela Conrado, Kamal Srinivasan, Jurriaan Brouwer-Visser, Hong Yan, Hesham Mohamed, Aafia Chaudhry, Srikanth Ambati, Lutz Harnisch, John D Davis
Journal: Blood
Blood (2023) 142 (Supplement 1): 1436.
https://doi.org/10.1182/blood-2023-180675
Published: 2023
Journal Articles

Results of a Second, Prespecified Analysis of the Phase 2 Study ELM-2 Confirm High Rates of Durable Complete Response with Odronextamab in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) with Extended Follow-up

Jose. C. Villasboas, Tae Min Kim, Michal Taszner, Silvana Novelli, Seok-Goo Cho, Michele Merli, Ana Jimenez Ubieto, Benoit Tessoulin, Michelle Poon, Jan Walewski, Shuhua Yi, Yuqin Song, Geoffrey Chong, Stefano Luminari, Emmanuel Bachy, Stephanie Guidez, Aranzazu Alonso, Deepa Jagadeesh, Wei Zhang, Laura Magnano, Elżbieta Iskierka-Jażdżewska, Monica Tani, Jessica Cai, Amulya Uppala, Saleem Shariff, Lei Chi, Aafia Chaudhry, Hesham Mohamed, Srikanth Ambati, David Tucker
Journal: Blood
Blood (2023) 142 (Supplement 1): 3041.
https://doi.org/10.1182/blood-2023-181650
Published: 2023
Journal Articles

Health-Related Quality of Life and Symptoms in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with Odronextamab Monotherapy in the Phase 2 ELM-2 Study

Elzbieta Iskierka-Jazdzewska, Won Seog Kim, Seok-Goo Cho, Tae Min Kim, Isidro Jarque, Tadeusz Robak, Michelle Poon, H. Miles Prince, Sung Yong Oh, Francesca Lim, Cecilia Carpio, Tran-Der Tan, Sabarish Ayyappan, Antonio Gutiérrez, Huilai Zhang, Junning Cao, Mingzhi Zhang, Benoit Tessoulin, Jingjin Li, Cristina Ivanescu, Matthew Reaney, Aafia Chaudhry, Hesham Mohamed, Srikanth Ambati, James Harnett, Lei Chi, Jan Walewski
Journal: Blood
Blood (2023) 142 (Supplement 1): 4504.
https://doi.org/10.1182/blood-2023-180743
Published: 2023
Journal Articles

Maintenance of Moderate to High Levels of Functioning and Quality of Life with Odronextamab Monotherapy in Patients with Relapsed or Refractory Follicular Lymphoma

Benoit Tessoulin, Seok-Goo Cho, Michal Taszner, Tae Min Kim, Silvana Novelli, Jose C. Villasboas, Michele Merli, Ana Jimenez Ubieto, Michelle Poon, David Tucker, Jan Walewski, Shuhua Yi, Yuqin Song, Geoffrey Chong, Emmanuel Bachy, Stephanie Guidez, Aranzazu Alonso, Deepa Jagadeesh, Wei Zhang, Laura Magnano, Elzbieta Iskierka-Jazdzewska, Monica Tani, Jessica Cai, Cristina Ivanescu, Matthew Reaney, Aafia Chaudhry, Hesham Mohamed, Srikanth Ambati, James Harnett, Lei Chi, Stefano Luminari
Journal: Blood
Blood (2023) 142 (Supplement 1): 669.
https://doi.org/10.1182/blood-2023-181942
Published: 2023
Journal Articles

Odronextamab Demonstrates Durable Complete Responses in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Progressing after CAR-T Therapy: Outcomes from the ELM-1 Study

Jennifer L. Crombie, Matthew Matasar, Max S. Topp, John N. Allan, Jeffrey A. Barnes, Jon E. Arnason, Jean-Marie Michot, Neta Goldschmidt, Susan M. O'Brien, Uri Abadi, Irit Avivi Mazza, Jessica Cai, Dina M. Flink, Min Zhu, Jurriaan Brouwer-Visser, Hesham Mohamed, Aafia Chaudhry, Srikanth Ambati, Steve M Ansell
Journal: Blood
Blood (2023) 142 (Supplement 1): 4461.
https://doi.org/10.1182/blood-2023-181602
Published: 2023
Journal Articles

Trial in Progress: Phase 1 Trial Evaluating the Safety and Tolerability of Odronextamab in Combination with Cemiplimab in Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

Cecilia Carpio, Manjusha Namuduri, Nazia Iqbal, Dishan Liu, Nickolas Sophos, Min Zhu, Ayesha Sabir, Jurriaan Brouwer-Visser, Aafia Chaudhry, Hesham Mohamed, Alejandro Martín García-Sancho
Journal: Blood
Blood (2023) 142 (Supplement 1): 3100.
https://doi.org/10.1182/blood-2023-179964
Published: 2023
Journal Articles

Final Analysis of the Phase 2 ELM-2 Study: Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Sabarish Ayyappan, Won Seog Kim, Tae Min Kim, Jan Walewski, Seok-Goo Cho, Isidro Jarque, Elzbieta Iskierka-Jazdzewska, Michelle Poon, Sung Yong Oh, Francesca Lorraine Wei Inng Lim, Cecilia Carpio, Tran-Der Tan, Antonio Gutiérrez, Huilai Zhang, Junning Cao, Mingzhi Zhang, Benoit Tessoulin, Jingjin Li, Melanie Ufkin, Saleem Shariff, Lei Chi, Aafia Chaudhry, Hesham Mohamed, Srikanth Ambati, H. Miles Prince
Journal: Blood
Blood (2023) 142 (Supplement 1): 436.
https://doi.org/10.1182/blood-2023-179818
Published: 2023
Journal Articles

Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Results from a Prespecified Analysis of the Pivotal Phase II Study ELM-2

Won-Seog Kim, Tae Min Kim, Seok-Goo Cho, Isidro Jarque, Elżbieta Iskierka-Jażdżewska, Michelle Limei Poon, H. Miles Prince, Sung Yong Oh, Francesca Lim, Cecilia Carpio, Tran-Der Tan, Sabarish Ayyappan, Antonio Gutierrez, Jingjin Li, Melanie Ufkin, Min Zhu, Aafia Chaudhry, Hesham Mohamed, Srikanth R. Ambati, Jan Walewski
Journal: Blood
Blood (2022) 140 (Supplement 1): 1070–1071.
https://doi.org/10.1182/blood-2022-158406
Published: 2022
Journal Articles

Odronextamab in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Grade 1-3a: Results from a Prespecified Analysis of the Pivotal Phase II Study ELM-2

Tae Min Kim, Michal Taszner, Seok-Goo Cho, Silvana Novelli, Steven Le Gouill, Michelle Limei Poon, Jose C. Villasboas, Rebecca Champion, Emmanuel Bachy, Stéphanie Guidez, Aránzazu Alonso Alonso, Deepa Jagadeesh, Michele Merli, David Tucker, Jingxian Cai, Carolina Leite De Oliveira, Min Zhu, Aafia Chaudhry, Hesham Mohamed, Srikanth R. Ambati, Stefano Luminari
Journal: Blood
Blood (2022) 140 (Supplement 1): 2280–2282.
https://doi.org/10.1182/blood-2022-158404
Published: 2022
Journal Articles

Evaluate Dynamics of IL-6 Release during Step-up Dosing of Subcutaneous Administration of Odronextamab Via a Quantitative Systems Pharmacology Modeling Approach

Masood Khaksar Toroghi, Min Zhu, Srikanth R. Ambati, Hesham Mohamed, Aafia Chaudhry, Hong Yan, John D. Davis, A. Thomas DiCioccio
Journal: Blood
Blood (2022) 140 (Supplement 1): 11912–11913.
https://doi.org/10.1182/blood-2022-158413
Published: 2022
Journal Articles

Trial in Progress: Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Systemic Therapy from Real-World Experience (ORCHID)

Catherine Thieblemont, Qiufei Ma, Christian Hampp, James Harnett, Rachel E. Sobel, Jessica J. Jalbert, Ruben G.W. Quek, Wenhui Wei, Ning Wu, Vera Mastey, Joy Wang, Anit Bajwa, Benedikt Maissenhaelter, Chantal van Gils, Shivani Aggarwal, Aafia Chaudhry, Hesham Mohamed, Srikanth R. Ambati, Emmanuel Bachy, Gandhi Laurent Damaj
Journal: Blood
Blood (2022) 140 (Supplement 1): 8065–8067.
https://doi.org/10.1182/blood-2022-158418
Published: 2022
Journal Articles

Modeling and Simulation in Support of Odronextamab Subcutaneous Dose Selection for Adult Patients with Indolent or Aggressive Non-Hodgkin Lymphoma

Min Zhu, Srikanth R. Ambati, Hesham Mohamed, Masood Khaksar Toroghi, Hong Yan, Aafia Chaudhry, John D. Davis
Journal: Blood
Blood (2022) 140 (Supplement 1): 11579–11580.
https://doi.org/10.1182/blood-2022-158409
Published: 2022
Journal Articles

Selection of Odronextamab Pediatric Dosing Regimens for Aggressive Non-Hodgkin Lymphoma Via a Modeling and Simulation Approach

Min Zhu, Michael Dodds, Srikanth R. Ambati, Hesham Mohamed, Jason Chittenden, Hong Yan, Aafia Chaudhry, John D. Davis
Journal: Blood
Blood (2022) 140 (Supplement 1): 8855–8856.
https://doi.org/10.1182/blood-2022-158416
Published: 2022
Journal Articles

Trial in Progress: Follicular Lymphoma Outcomes in Relapsed/Refractory Patients Treated with Systemic Therapy in a Real-World Assessment (FLORA)

Emmanuel Bachy, Gandhi Laurent Damaj, Qiufei Ma, Christian Hampp, James Harnett, Rachel E. Sobel, Jessica J. Jalbert, Ruben G.W. Quek, Wenhui Wei, Ning Wu, Vera Mastey, Joy Wang, Anit Bajwa, Benedikt Maissenhaelter, Chantal van Gils, Shivani Aggarwal, Aafia Chaudhry, Hesham Mohamed, Srikanth R. Ambati, Catherine Thieblemont
Journal: Blood
Blood (2022) 140 (Supplement 1): 5198–5200.
https://doi.org/10.1182/blood-2022-158419
Published: 2022
Journal Articles

A Quantitative Systems Pharmacology Modeling Framework for Evaluation of Cytokine Release Mediated By Intravenous Odronextamab Monotherapy in Patients with B-Cell Non-Hodgkin Lymphoma

Masood Khaksar Toroghi, Min Zhu, Jurriaan Brouwer-Visser, Srikanth R. Ambati, Hesham Mohamed, Aafia Chaudhry, John D. Davis, A. Thomas DiCioccio
Journal: Blood
Blood (2022) 140 (Supplement 1): 11930–11931.
https://doi.org/10.1182/blood-2022-158412
Published: 2022
Journal Articles

Optimization of Intravenous Odronextamab Step-up Regimen for Reducing the Risk of High-Grade Cytokine Release Syndrome

Min Zhu, Jurriaan Brouwer-Visser, Srikanth R. Ambati, Hesham Mohamed, Vladimir Jankovic, Fang Wang, Hong Yan, Jingxian Cai, Carolina Leite De Oliveira, Melanie Ufkin, John D. Davis, Aafia Chaudhry, Masood Khaksar Toroghi
Journal: Blood
Blood (2022) 140 (Supplement 1): 11560–11561.
https://doi.org/10.1182/blood-2022-158415
Published: 2022
Journal Articles

Olutasidenib (FT-2102) Induces Rapid Remissions in Patients with IDH1-Mutant Myelodysplastic Syndrome: Results of Phase 1/2 Single Agent Treatment and Combination with Azacitidine

Jorge E. Cortes, MD, Eunice S. Wang, MD, Justin M. Watts, MD, Sangmin Lee, MD, Maria R. Baer, MD, Kim-Hien Dao, DO, PhD, Shira Dinner, MD, Jay Yang, MD, William B. Donnellan, MD, Anthony P Schwarer, MD MBBS (Hons), FRACP, FRCPA, Christian Recher, MD PhD, Patrick Kelly, MD, Jennifer Sweeney, Julie Brevard, Patrick Henrick, Sanjeev Forsyth, Sylvie Guichard, Hesham Mohamed, MD, Andrew H. Wei, PhD FRACP, FRCPA, MBBS
Journal: Blood
Blood (2019) 134 (Supplement_1): 674.
https://doi.org/10.1182/blood-2019-124360
Published: 2019
Journal Articles

Olutasidenib (FT-2102), an IDH1m Inhibitor As a Single Agent or in Combination with Azacitidine, Induces Deep Clinical Responses with Mutation Clearance in Patients with Acute Myeloid Leukemia Treated in a Phase 1 Dose Escalation and Expansion Study

Justin M. Watts, MD, Maria R. Baer, MD, Jay Yang, MD, Thomas Prebet, MD PhD, Sangmin Lee, MD, Gary J. Schiller, MD, Shira Dinner, MD, Arnaud Pigneux, Pau Montesinos, MD PhD, Eunice S. Wang, MD, Karen Seiter, MD, Andrew H. Wei, PhD FRACP, FRCPA, MBBS, Stephane De Botton, Montserrat Arnan Sangerman, William B. Donnellan, MD, Brian A Jonas, MD PhD, Paul Brent Ferrell, Jr., MD, Kim-Hien Dao, DO, PhD, Patrick Kelly, MD, Jennifer Sweeney, Sanjeev Forsyth, Sylvie Guichard, Julie Brevard, Patrick Henrick, Hesham Mohamed, MD, Jorge E. Cortes, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 231.
https://doi.org/10.1182/blood-2019-123920
Published: 2019
Journal Articles

FT-2102, an IDH1m Inhibitor, in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Ayndrome (MDS): Results from a Phase 1 Study

Jorge E. Cortes, MD, Justin Watts, MD, Thomas Prebet, MD PhD, Gary J. Schiller, MD, Sangmin Lee, MD, Jay Yang, MD, Eunice S. Wang, MD, Shira Dinner, MD, Paul Brent Ferrell, Jr., MD, Will Donnellan, MD, Brian A. Jonas, MD PhD, Andrew H Wei, MBBS, PhD, Pau Montesinos, MD PhD, Montserrat Arnan Sangerman, MD, Patrick Kelly, MD, Ping Li, PhD, Jennifer Sweeney, Courtney Watson, Hesham Mohamed, MD, Maria R. Baer, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1452.
https://doi.org/10.1182/blood-2018-99-114126
Published: 2018